Physician profile
Phuc V Le
NPI 1487691085
$4,358.17
in general payments reported to CMS, 2019-2025
17 companies · $671 in 2025
The $671 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $213 · 2021: $639 · 2022: $397 · 2023: $1,527 · 2024: $727 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,221.04 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $689.60 | 2021-2025 | Dailies Total1, Dailies, Precision 1 |
| Coopervision INC. | $592.91 | 2022-2025 | Misight Contact Lens, Ortho-K Contact Lens, Cvi Contact Lens |
| Oyster Point Pharma, INC. | $414.58 | 2022-2023 | Tyrvaya |
| Visioneering Technologies, INC. | $373.42 | 2021-2025 | |
| Horizon Therapeutics Plc | $247.08 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $150.00 | 2023 | Xelpros, Cequa, Bromsite |
| Tarsus Pharmaceuticals, INC. | $133.23 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $123.88 | 2021 | |
| Optos, INC. | $115.48 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $80.95 | 2019-2020 | |
| Glaukos Corporation | $52.24 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Menicon America INC | $45.48 | 2019 | |
| Abbvie INC. | $37.24 | 2023-2024 | |
| Plexus Optix, INC. | $36.70 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $23.91 | 2020 | |
| Abb Con-Cise Optical Group LLC | $20.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phuc Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.